uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Revenue of uniQure N.V. (QURE)
Revenue in 2023 (TTM): $15.84 M
According to uniQure N.V.'s latest financial reports the company's current revenue (TTM) is $15.84 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of uniQure N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $15.84 M | $2.22 M | $-253,100,000 | $-306,557,000 | $-308,478,000 |
| 2022 | $106.48 M | $103.14 M | $-108,018,000 | $-128,259,000 | $-126,789,000 |
| 2021 | $524 M | $499.03 M | $319 M | $332.81 M | $329.59 M |
| 2020 | $37.51 M | $-84,886,000 | $-126,970,000 | $-141,443,000 | $-125,024,000 |
| 2019 | $7.28 M | $-87,456,000 | $-113,791,000 | $-124,201,000 | $-128,011,000 |
| 2018 | $11.28 M | $-61,776,000 | $-74,013,000 | $-83,073,000 | $-83,304,000 |
| 2017 | $13.11 M | $-54,302,000 | $-69,737,000 | $-80,588,000 | $-80,389,000 |
| 2016 | $25.1 M | $-47,592,000 | $-63,968,000 | $-72,229,000 | $-73,374,000 |
| 2015 | $10.3 M | $9.67 M | $-72,475,732 | $-78,620,471 | $-78,149,258 |
| 2014 | $5.7 M | $-37,879,982 | $-45,713,000 | $-45,041,101 | $-45,041,101 |
| 2013 | $4.06 M | $2.96 M | $-33,706,892 | $-37,034,991 | $-37,034,991 |
| 2012 | $ | $-13,489,353 | $-18,091,750 | $-19,462,004 | $-19,462,004 |
| 2011 | $ | $ | $-22,632,677 | $-22,422,396 | $-22,422,396 |